BIOTRONIK Announces FDA Approval of Renamic Neo with LiveSupport Software

Wednesday, April 27, 2022

BIOTRONIK, Inc. announced today it has received U.S. Food and Drug Administration (FDA) approval of Renamic Neo, the company's state-of-the-art programmer for implanted cardiac rhythm management devices such as ICDs, pacemakers, and implantable cardiac monitors.

In addition to its programming functions, Renamic Neo now offers LiveSupport, which allows clinicians to share the programmer screen with, or grant programmer control to, BIOTRONIK technical support personnel at remote locations. Renamic Neo is also compatible with BIOTRONIK's ReportShare and EHR DataSync to allow secure and easy integration of programmer data into hospitals' EHR systems.

"The Renamic Neo programmer represents another advancement in providing clinicians with better tools to improve patient care," said Dr. Sei Iwai, Section Chief Cardiac Electrophysiology, at Westchester Medical Health Network, Valhalla, New York. "The LiveSupport feature, ReportShare, and EHR DataSync, plus all the connectivity options in this programmer, can improve our workflow and response time. The Renamic Neo programmer is exactly the tool we need in our device clinic."

The Renamic Neo programmer boasts a 12" high-resolution, high-contrast, LCD touch screen display, a built-in analyzer, and battery-powered portability, as well as various connectivity options. In addition, Renamic Neo is significantly lighter and smaller than its predecessor.

Renamic Neo will soon be available in the United States to hospitals and clinics that implant BIOTRONIK cardiac rhythm management devices.

Latest Issue
Get instant
access to our latest e-book
Sanofi UpperEdge - Healthcare ERP Transformation Medical Manufacturing Asia 2022 Medical Fair Asia 2022